Bio: I agree on the IPO route!! I think the Diagnostic Division is going to present a very appealing opportunity to investors by April or May. By then our MS diagnostic will have been validated and ready for commercial launch. Gerald seems to feel it's revenue will ramp up much, much faster than our Alzheimers revenue. But, by 3 months from now we'll have the Georgetown tests validated and ready for RUO use by pharma! Cornering the market on Alzheimer's diagnostics is a pretty appealing opportunity for investors in an IPO as well.